BridgeBio signs voluntary agreement with US government to expand Medicaid access to Attruby

• BridgeBio entered a voluntary agreement with the U.S. government to expand access to its marketed medicine via the GENEROUS Model.
• Deal targets broader Medicaid access, lower costs for uninsured patients.
• Company expects no future pricing mandates under the agreement; specific terms remain confidential.
• Attruby to remain available through Medicare Part D without future pricing mandates.
• ForgingBridges copay assistance program unchanged, supporting qualifying patients with out-of-pocket costs as low as $0 monthly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-035055), on August 31, 2026, and is solely responsible for the information contained therein.